Centogene NV
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community
Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
Worldwide 120 study sites marks this as the largest observational study for genetics in PD
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced reaching a significant milestone with the recruitment and genetic testing of 12,500 participants in the Rostock International Parkinson's Disease (ROPAD) Study. With more than 120 study sites around the world, CENTOGENE is leading the largest study of its kind a global observational study focused on the role of genetics in Parkinson's disease (PD). As part of the ROPAD study, CENTOGENE utilizes CentoCard, its proprietary, CE-marked dried blood spot collection kit in combination with state-of-the-art sequencing technologies to develop a first-in-class Parkinsons Disease Panel that is being used to screen participants for mutations in leucine-rich repeat kinase 2 (LRRK2) as well as other PD-associated genes. CENTOGENEs Parkinsons Disease Panel has been widely adopted by clinicians, and its use could provide vital information to allow more precise therapeutic development in the future.
Having met the initial milestone of recruiting and performing genetic testing of 10,000 participants in March 2021, CENTOGENE and Denali Therapeutics extended their partnership to recruit and test an additional 2,500 patients. In 2018, CENTOGENE entered a strategic collaboration with Denali Therapeutics for the targeted global identification of PD patients with mutations in the LRRK2 gene. The LRRK2 gene is one of the most common mutated genes in familial PD.
Story continues
Patients enrolled in ROPAD and identified with a LRRK2 mutation may be eligible for participation in future therapeutic clinical studies. CENTOGENE conducts clinical studies with biopharma partners around the world, such as Denali Therapeutics, who are currently evaluating the efficacy and safety of a small molecule, LRRK2 inhibitor, which aims to slow the progression of PD in individuals with a pathogenic mutation in LRRK2 in the LIGHTHOUSE study. More information about LIGHTHOUSE (NCT05418673) is available at ClinicalTrials.gov.
Parkinsons disease is a devastating neurodegenerative disease, and there is a significant medical need to truly unveil deeper data on PD genetics to accelerate diagnosis and personalized Parkinsons treatments, said Kim Stratton, Chief Executive Officer at CENTOGENE. In reaching such a pivotal milestone in our Parkinsons disease study, we have been able to unlock significant insights into the genetic factors which we believe together with partners, such as Denali with their therapeutics targeting LRRK2, will accelerate the development of potentially life-saving therapeutics for many PD patients around the world.
More than 10 million people worldwide are affected by Parkinsons disease, many of which are tied to genetic factors, like LRRK2, said Carole Ho, M.D., Chief Medical Officer at Denali. In combining forces with CENTOGENE, we have unlocked significant insights and are committed to working together towards a unified goal of accelerating the development of potentially life-saving therapeutics for PD patients around the world.
About ROPAD
The Rostock International Parkinson's Disease Study (ROPAD) is a global epidemiological study focusing on the role of genetics in Parkinson's disease (PD). The major goal of the study is to characterize the genetics of PD to establish a better understanding of the disease etiology, diagnosis, and severity.
CENTOGENE utilizes CentoCard, the Companys proprietary, CE-marked dried blood spot collection kit in combination with state-of-the-art sequencing technologies to screen for mutations in LRRK2 and other PD-associated genes. This is based on insights powered by the CENTOGENE Biodatabank, what the Company believes to be the worlds largest real-world data repository for rare and neurodegenerative diseases. Throughout this study, 12,500 participants from around the world have been tested over a circa three-year period.
Patients with mutations in PD genes are offered further clinical assessment in a supplementary study, Lbeck International Parkinsons Disease Project (LIPAD), conducted at the University of Lbeck where a detailed phenotyping of participants is being performed. Patients enrolled in ROPAD and identified with a LRRK2 mutation may be eligible for participation in future therapeutic clinical studies. CENTOGENE conducts clinical studies with biopharma partners around the world, such as Denali Therapeutics, who are currently developing a small molecule, LRRK2 inhibitor for the treatment of PD.
To learn more about ROPAD, visit: https://www.centogene.com/pharma/clinical-trial-support/rostock-international-parkinsons-disease-study-ropad
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit http://www.denalitherapeutics.com.
About CENTOGENE
CENTOGENE (Nasdaq: CNTG) is transforming real-world clinical, genetic, and multiomic data to enable better health outcomes for patients with rare and neurodegenerative diseases. For over 15 years, CENTOGENE has been providing diagnostic insights to patients with genetic diseases through our network of nearly 30,000 active physicians. CENTOGENE now believes its Biodatabank is the worlds largest real-world data repository of corresponding patients from more than 120 countries. Simplified logistics solutions, including CentoCard for sending biosamples, and our ISO, CAP, & CLIA certified state-of-the-art multiomic reference labs offer patients rapid and reliable diagnoses to support the identification and personalization of their treatments. Ultimately, offering the best treatment for patients involves developing new or better therapies. We are de-risking orphan drug discovery and development by partnering with more than 30 biopharma in target & drug screening, clinical development, market access and expansion. CENTOGENE engages in biodata partnerships with our Biodata Licenses and Insight Reports.
To discover more about our products, pipeline, and patient-driven purpose, visitwww.centogene.comand follow us onLinkedIn
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words anticipate, believe, continues, expect, estimate, intend, project, and similar expressions and future or conditional verbs such as will, would, should, could, might, can, and may, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENEs actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENEs business in general, see CENTOGENEs risk factors set forth in CENTOGENEs Form 20-F filed on March 31, 2022, with the Securities and Exchange Commission (the SEC) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENEs specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Media Contact:
CENTOGENEBen LeggCorporate CommunicationsPress@centogene.com
Lennart StreibelInvestor RelationsInvestor.Relations@centogene.com
Originally posted here:
CENTOGENE Reaches 12,500 Patient Milestone in Worlds Largest Observational Study on Parkinsons Disease Genetics - Yahoo Finance
- Could Genetics Influence Cancer Risk From Red and Processed Meats? - Technology Networks - March 19th, 2024
- Genetics of environmental sensitivity and its association with variations in emotional problems, autistic traits, and ... - Nature.com - March 19th, 2024
- The Global Parkinson's Genetics Program and Psomagen Inc. Make Agreement with Goal to Transform Parkinson's ... - PR Newswire - March 19th, 2024
- SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear ... - Yahoo Finance - March 19th, 2024
- Mindfulness in your DNA? Capacity to be present is partly a function of genetics, study finds - PsyPost - March 19th, 2024
- Are your cattle genetics protected from the lab-grown meat industry? - Agweek - January 23rd, 2024
- AI Harnesses Tumor Genetics to Predict Treatment Response - University of California San Diego - January 23rd, 2024
- The Role of Genetics in Cancer Care Continues to Expand - OncLive - January 23rd, 2024
- Jeremy Allen White's Plush Pout Is Thanks to Genetics and This $20 Lip Salve - InStyle - January 23rd, 2024
- Seed Experimentation and Genetics Videos Mother Earth News - Mother Earth News - January 23rd, 2024
- Kansas professor highlights role of genetics in the sustainable cow herd - Canadian Cattlemen - January 23rd, 2024
- Raha Kapoor's blue eyes remind fans of her great-grandfather, Raj Kapoor; here's what genetics says - IndiaTimes - December 29th, 2023
- Cell perturbation and lasers illuminate the genetics of latent blood cell traits - Nature.com - December 29th, 2023
- BASIC GENETICS INFORMATION - Understanding Genetics - NCBI Bookshelf - December 20th, 2023
- What is Genetics? | AMNH - American Museum of Natural History - December 20th, 2023
- Genetics of host plants determine what microorganisms they attract, finds study - Phys.org - December 20th, 2023
- Perception of genomic newborn screening among peripartum mothers | European Journal of Human Genetics - Nature.com - December 20th, 2023
- Growing Cotton in Space: How breakthroughs in plant genetics could lead to more resilient crops on Earth - RFD-TV - December 20th, 2023
- Study sheds light on the ancestry and genetics of Coast Salish woolly dogs | News | Vancouver Island University ... - Vancouver Island University News - December 20th, 2023
- Early bird, night owl behavior influenced by genetics, lead to varying levels of productivity - The Campanile - December 20th, 2023
- Psoriasis: Whats the Genetic Link? - Healthline - December 27th, 2022
- Healthline: Medical information and health advice you can trust. - December 27th, 2022
- Deep Dive Ties Together Dog Genetics, Brain Physiology and Behavior to Explain Why Collies Are Different from Terriers - Scientific American - December 10th, 2022
- Genetics - breast cancer - October 29th, 2022
- JK Agri Genetics reports standalone net loss of Rs 15.77 crore in the September 2022 quarter - Business Standard - October 21st, 2022
- Age Vs. Genetics: Which Is More Important For How You Age? - Patch - October 13th, 2022
- Global Animal Genetics Market is estimated to garner a revenue of ~USD 10067 Million by the end of 2033; Growing Prevalence of Animal Infectious... - October 13th, 2022
- Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome - Nature.com - October 13th, 2022
- ASHG 2022 in Los Angeles brings together researchers from around the world to advance discoveries in genetics, genomics research - EurekAlert - October 13th, 2022
- Those who invested in Fulgent Genetics (NASDAQ:FLGT) five years ago are up 833% - Yahoo Finance - October 13th, 2022
- Global Biobank Meta-analysis Initiative making genome-wide association studies more diverse and representative - EurekAlert - October 13th, 2022
- Optimal for His Genetics Legendary Bodybuilder Ronnie Coleman Once Got His Genes Tested and Received Interesting Results - EssentiallySports - October 13th, 2022
- Breast Cancer Awareness | Surgeons see increase of genetic instances of disease - Meadville Tribune - October 13th, 2022
- About Bad Chest Genetics, and Whether You Can Fix Them - Healthline - October 4th, 2022
- Tissue-specific impacts of aging and genetics on gene expression patterns in humans - Nature.com - October 4th, 2022
- Genetics of human evolution wins 2022 Nobel Prize in physiology or medicine - Science News Magazine - October 4th, 2022
- Stroke genetics informs drug discovery and risk prediction across ancestries - Nature.com - October 4th, 2022
- Illumina aims to push genetics beyond the lab with $200 genome - The Spokesman Review - October 4th, 2022
- $2.6M DOE Grant Supports UMD-led Study on Genetics of Plant Growth - Maryland Today - October 4th, 2022
- Are Kinks Hereditary? What Science Says About the Genetics of Desire - Glamour - October 4th, 2022
- Study on rare genetic diseases among diverse demographics in India - The Hindu - October 4th, 2022
- Howard University's Office of Research Awarded $11.5 Million From Chan Zuckerberg Initiative To Advance Genomics And Genetics Research - The Dig - October 4th, 2022
- The real power ofimproved genetics - Farming Life - October 4th, 2022
- CIA Just Invested In Woolly Mammoth Resurrection Tech - The Intercept - October 4th, 2022
- Fighting the Monkeypox Virus: Genetics as a Predictor of Vaccinia Vaccine Effectiveness - Medical News Bulletin - October 4th, 2022
- Improved pea reference genome and pan-genome highlight genomic features and evolutionary characteristics - Nature.com - September 25th, 2022
- SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event - GlobeNewswire - September 25th, 2022
- TU Researchers connect genetic ancestry with prostate tumors - Tuskegee University - September 25th, 2022
- Large-scale and small-scale population genetic structure of the medically important gastropod species Bulinus truncatus (Gastropoda, Heterobranchia) -... - September 25th, 2022
- Purrsonalised health: The startups and VCs betting on pet genetics - Sifted - September 16th, 2022
- Uncovering the genetic basis of mental illness requires data and tools that aren't just based on white people - Down To Earth Magazine - September 16th, 2022
- Solving medical mysteries with genetics: The Penn Neurogenetics Therapy Center | Penn Today - Penn Today - September 16th, 2022
- CHOPs new bird-proofed skyscraper will focus on vaccine and genetics research - The Philadelphia Inquirer - September 16th, 2022
- Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with Cancer - PR Newswire - September 16th, 2022
- Preimplantation Genetic Testing Market: Growing Demand for Genetically Testing and Rising Knowledge of Genetics to Drive the Market - BioSpace - September 16th, 2022
- People with ME invited to take part in major genetic study - The Independent - September 16th, 2022
- Can genetics breathe new life into giant river prawn production? - The Fish Site - September 16th, 2022
- Hybrid genetics is the future of UK beef, legendary US rancher says - FarmingUK - September 16th, 2022
- How geneticists can gain greater buy-in from the autistic community - Spectrum - September 16th, 2022
- Ancient Viking poop helped scientists map the genetics of a 5000-year-old parasite - Interesting Engineering - September 8th, 2022
- Project Uses OpenCDS, Chatbots to Broaden Genetic Testing's Reach - Healthcare Innovation - September 8th, 2022
- The power of genetics to unleash the potential of indoor farming - Vertical Farm Daily - September 8th, 2022
- Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care - OncLive - September 8th, 2022
- Ticking away in the back of my mind: what does it mean to know the risk embedded in your DNA? - The Guardian - September 8th, 2022
- How are genetic technologies being applied to combat infectious diseases in aquaculture? - The Fish Site - September 8th, 2022
- CCMB zeroes in on major genetic causes of male infertility - The Hans India - September 8th, 2022
- In Brief This Week: Illumina, Interpace, Genetic Signatures, Guardant Health, More - GenomeWeb - September 8th, 2022
- Atossa Genetics (ATOS) Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Inves - Benzinga - September 8th, 2022
- Genetics - National Institute of General Medical Sciences (NIGMS) - August 30th, 2022
- The genetics behind why some people get sicker with COVID-19 than others - ABC News - August 30th, 2022
- Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have... - August 30th, 2022
- Is COVID-19 Loss of Smell Genetic? What Research Shows - Healthline - August 30th, 2022
- Principal Component Analyses (PCA)-based findings in population genetic studies are highly biased and must be reevaluated | Scientific Reports -... - August 30th, 2022
- You're in control: Exercise outweighs genetics when it comes to longer life - Study Finds - August 30th, 2022
- An international team sets out to cure genetic heart diseases with one shot - Freethink - August 30th, 2022
- Olufunmilayo I. Olopade, MD: Cutting Into Breast Cancer Disparities With Genetic Testing - Everyday Health - August 30th, 2022
- Yale Study Suggests That Evolution Can Be Predicted - SciTechDaily - August 30th, 2022
- Could Genetics Be the Key to Never Getting the Coronavirus? - The Atlantic - July 27th, 2022
- Noonan appointed Kent Professor of Genetics and Professor of Neuroscience - Yale News - July 27th, 2022
- Happy 200th birthday, Gregor Mendel: 5 ways the father of modern genetics impacted your life today - Clemson News - July 27th, 2022